Side-by-side · Research reference

CerebrolysinvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED11/65 cited

BPhase 3HUMAN-REVIEWED8/39 cited

Cerebrolysin

Porcine Brain-Derived Peptide Mix · Phase 3

30 mL/dayStandard doseAfridi 2026 Staszewski 2026

14–21 daysTreatment course

49% vs 35%mRS 0-2 at 12 moStaszewski 2026

IV infusion · 100-250 mL saline · Daily

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Cerebrolysin

Thymosin α-1

Primary target

Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis

—

Origin

Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented

—

02Dosage Protocols

Parameter

Cerebrolysin

Thymosin α-1

Standard dose (stroke)

30–50 mL / day IVStaszewski 2026 Afridi 2026

Most trials use 30 mL in 100-250 mL saline over 30-60 min.

—

Lower dose (dementia)

10–20 mL / day IV or IMKhatkova 2026

Chronic neurodegenerative conditions; intermittent courses.

—

High dose (TBI)

50 mL / day IVKobayashi 2025

CLINCH trial protocol for intracerebral hemorrhage.

—

Duration

10–21 days (acute); intermittent courses (chronic)

Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.

6–12 months for chronic indications

Timing (stroke)

Initiate within 12 hrs of symptom onset; up to 6 hrs optimal

Earlier initiation associated with better outcomes.

—

Adjunct to thrombectomy

30-50 mL daily × 10-14 days, starting day of EVT

Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.

—

Evidence basis

Phase 3 RCT + observational

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Administration route

IV infusion (preferred) or IM injection

IV allows higher doses; IM used in outpatient/chronic settings.

—

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Frequency

—

2× weekly (Mon/Thu typical)

Lower / starter dose

—

0.8 mg per injection

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

04Side Effects & Safety

Parameter

Cerebrolysin

Thymosin α-1

Injection site reaction

Mild pain, erythema (IM route)

Erythema, mild discomfort

Infusion reaction

Rare: flushing, transient hypotension during rapid IV

—

Agitation / Restlessness

Reported in <5% of patients; typically mild, self-limited

—

Headache

Mild, transient; incidence not significantly elevated vs placeboPatel 2025

—

Serious adverse events

No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)

—

Hemorrhagic transformation

Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025

—

Mortality

No increase; meta-analysis RR 0.89 (0.68-1.18)

—

Allergic reaction

Rare; porcine origin theoretically immunogenic but clinically insignificant

—

Seizure risk

Not elevated; safe in epilepsy populations

—

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

Cerebrolysin

·Known hypersensitivity to porcine-derived products
·Active seizure disorder (relative — caution advised)

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Cerebrolysin

·Severe renal impairment (amino acid load — monitor)
·Pregnancy / lactation (insufficient safety data)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Cerebrolysin

Thymosin α-1

1. Preparation (IV infusion)

Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Infusion rate

Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. IM injection (alternative)

For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.

2× weekly, e.g. Monday + Thursday.

4. Timing

Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Storage

Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.

27–31G, 4–8 mm insulin syringe.

6. Co-administration

Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.

—

06Stack Synergy

Cerebrolysin

+ Semax

Moderate

View Semax →

Cerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.

Cerebrolysin: 30 mL IV daily × 10-14 days
Semax: 300-600 mcg intranasal BID × 10-14 days
Timing: Concurrent during acute recovery phase
Primary benefit: Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI

+ BPC-157

Multi-pathway

View BPC-157 →

Cerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.

Cerebrolysin: 30-50 mL IV daily × 14 days
BPC-157: 250-500 mcg SQ daily × 14-28 days
Timing: Initiate both within 24-48 hrs of injury
Primary benefit: Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery

Thymosin α-1

— no documented stacks